Objective: To study growth response to growth hormone (GH) treatment in growth hormone-deficient (GHD) patients.
Patients And Methods: In total, 477 GHD children were included in the study. Patients were followed up for a minimum of 1 year and up to 6 years, anthropometric assessment was performed every 3 months, while thyroid profile was followed every 6 months. Student's t-test was used for analysis of two quantitative variables.
Results: Patients with complete GHD and multiple pituitary hormone deficiency were significantly shorter as expressed in their height standard deviation score (SDS), target height - height (SDS) and a more bone age delay. Patients with complete GHD showed better growth response compared with those with partial GHD in the first 2 years of therapy.
Conclusion: We conclude that anthropometric assessment is the cornerstone in GHD diagnosis and follow-up, where catch up growth occurs in the first 2 years of therapy followed by a plateau.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1515/jpem-2012-0091 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacological Aspects in the Management of Children and Adolescents with Prader-Willi Syndrome.
Paediatr Drugs
January 2025
Division of Endocrinology, Department of Pediatrics, University of Florida, PO Box 100296, Gainesville, FL, 32610, USA.
Prader-Willi syndrome is a rare neurodevelopmental disorder that impacts the musculoskeletal, endocrine, pulmonary, neurologic, ocular, and gastrointestinal systems. In addition, individuals with Prader-Willi syndrome have issues with cognitive development, characteristic behavioral problems, and perhaps most profoundly, appetite control. Currently, the only US Food and Drug Administration-approved therapy for Prader-Willi syndrome is growth hormone, which has been Food and Drug Administration approved for > 20 years for the treatment of growth failure in Prader-Willi syndrome.
View Article and Find Full Text PDFInavolisib: First Approval.
Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Inavolisib (Itovebi) is an orally administered, phosphatidylinositol-3-kinase alpha (PI3Kα) inhibitor being developed by Genentech, a member of the Roche group, for the treatment of solid tumours. On 10 October 2024, inavolisib received its first approval in the USA in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. In the EU and other countries worldwide, regulatory review of inavolisib is currently underway.
View Article and Find Full Text PDFCytokinin negatively regulates tomato fruit ripening by influencing the ethylene pathway.
Plant Cell Rep
January 2025
College of Life Sciences, Nanjing Agricultural University, Nanjing, 210095, China.
Reducing endogenous CK levels accelerates fruit ripening in tomato by regulating ethylene biosynthesis and signalling pathway. Tomato is a typical climacteric fruit and is recognized as one of the most important horticultural crops globally. The ripening of tomato fruits is a complex process, highly regulated by phytohormones.
View Article and Find Full Text PDFMolecular mechanisms affected by boron deficiency in root and shoot meristems of plants.
J Exp Bot
January 2025
University of Bonn, Institute for Crop Science and Resource Conservation, Crop Functional Genomics, Friedrich-Ebert-Allee 144, 53113 Bonn, Germany.
Boron deficiency is an abiotic stress that negatively impacts plant growth and yield worldwide. Boron deficiency primarily affects the development of plant meristems, groups of stem cells critical for all postembryonic tissue growth. The link between boron and meristem development was first established in 1923, when boron's essentiality was discovered.
View Article and Find Full Text PDFRespiratory complex I-mediated NAD regeneration regulates cancer cell proliferation through the transcriptional and translational control of p21 expression by SIRT3 and SIRT7.
Mol Oncol
January 2025
Division of Cancer Cell Biology, Department of Pharmaceutical Sciences, Showa University Graduate School of Pharmacy, Tokyo, Japan.
The role of the electron transport chain (ETC) in cell proliferation control beyond its crucial function in supporting ATP generation has recently emerged. In this study, we found that, among the four ETC complexes, the complex I (CI)-mediated NAD regeneration is important for cancer cell proliferation. In cancer cells, a decrease in CI activity by RNA interference (RNAi) against NADH:ubiquinone oxidoreductase core subunit V1 (NDUFV1) arrested the cell cycle at the G/S phase, accompanying upregulation of p21 cyclin-dependent kinase inhibitor expression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!